Combination chemotherapy of S-1 and taxanes in Korea

Yeul Hong Kim, Hoon K. Kim

Research output: Contribution to journalArticle

Abstract

Various combination treatments incorporating S-1 are undergoing clinical trials in Korea, especially combinations with taxane, oxaliplatin, or irinotecan. In a phase I study to estimate the maximum tolerated dose of docetaxel in combination with S-1 administered at a fixed dose of 40 mg/m 2 twice daily on days 1-14 of each 3-week cycle in patients with advanced gastric cancer, 60 mg/m2 docetaxel was declared to be the maximum tolerated dose. A phase I/II study of the same schedule of combination chemotherapy with S-1 plus docetaxel reported doses of S-1/docetaxel of 40/75 mg/m2 as the maximum tolerated dose. In a phase I study of S-1 plus weekly docetaxel, the patients received variable doses of docetaxel administered intravenously over 1 h on days 1 and 8 and S-1 administered on days 1-14 of each 3-week cycle. The maximum-tolerated doses of S-1 and docetaxel were determined to be 45 mg/m2 and 35 mg/m2 in this study. A phase I/II study of docetaxel plus S-1 combination chemotherapy from Korea reported a response rate of 43.3%. Also, a phase II study of paclitaxel plus S-1 as first-line therapy in patients with advanced or relapsed gastric cancer showed an overall response rate of 49%. The most frequent significant toxicities in combination chemotherapies with taxane plus S-1 were neutropenia and febrile neutropenia. However, nonhematological toxicities were mild to moderate. A taxane plus S-1 combination regimen could be a new standard regimen for advanced gastric cancer, given its significant activity and favorable toxicity pattern.

Original languageEnglish
Pages (from-to)31-37
Number of pages7
JournalGastric Cancer
Volume12
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2009 Jan 1

Fingerprint

docetaxel
Taxoids
Korea
Combination Drug Therapy
Maximum Tolerated Dose
Stomach Neoplasms
oxaliplatin
irinotecan
Febrile Neutropenia
Paclitaxel
Neutropenia

Keywords

  • Combination chemotherapy
  • Docetaxel
  • Gastric neoplasm
  • Paclitaxel
  • S-1

ASJC Scopus subject areas

  • Cancer Research
  • Gastroenterology
  • Oncology

Cite this

Combination chemotherapy of S-1 and taxanes in Korea. / Kim, Yeul Hong; Kim, Hoon K.

In: Gastric Cancer, Vol. 12, No. SUPPL. 1, 01.01.2009, p. 31-37.

Research output: Contribution to journalArticle

Kim, Yeul Hong ; Kim, Hoon K. / Combination chemotherapy of S-1 and taxanes in Korea. In: Gastric Cancer. 2009 ; Vol. 12, No. SUPPL. 1. pp. 31-37.
@article{60d903c9a351445ab371c03a23db6927,
title = "Combination chemotherapy of S-1 and taxanes in Korea",
abstract = "Various combination treatments incorporating S-1 are undergoing clinical trials in Korea, especially combinations with taxane, oxaliplatin, or irinotecan. In a phase I study to estimate the maximum tolerated dose of docetaxel in combination with S-1 administered at a fixed dose of 40 mg/m 2 twice daily on days 1-14 of each 3-week cycle in patients with advanced gastric cancer, 60 mg/m2 docetaxel was declared to be the maximum tolerated dose. A phase I/II study of the same schedule of combination chemotherapy with S-1 plus docetaxel reported doses of S-1/docetaxel of 40/75 mg/m2 as the maximum tolerated dose. In a phase I study of S-1 plus weekly docetaxel, the patients received variable doses of docetaxel administered intravenously over 1 h on days 1 and 8 and S-1 administered on days 1-14 of each 3-week cycle. The maximum-tolerated doses of S-1 and docetaxel were determined to be 45 mg/m2 and 35 mg/m2 in this study. A phase I/II study of docetaxel plus S-1 combination chemotherapy from Korea reported a response rate of 43.3{\%}. Also, a phase II study of paclitaxel plus S-1 as first-line therapy in patients with advanced or relapsed gastric cancer showed an overall response rate of 49{\%}. The most frequent significant toxicities in combination chemotherapies with taxane plus S-1 were neutropenia and febrile neutropenia. However, nonhematological toxicities were mild to moderate. A taxane plus S-1 combination regimen could be a new standard regimen for advanced gastric cancer, given its significant activity and favorable toxicity pattern.",
keywords = "Combination chemotherapy, Docetaxel, Gastric neoplasm, Paclitaxel, S-1",
author = "Kim, {Yeul Hong} and Kim, {Hoon K.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s10120-008-0464-9",
language = "English",
volume = "12",
pages = "31--37",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Combination chemotherapy of S-1 and taxanes in Korea

AU - Kim, Yeul Hong

AU - Kim, Hoon K.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Various combination treatments incorporating S-1 are undergoing clinical trials in Korea, especially combinations with taxane, oxaliplatin, or irinotecan. In a phase I study to estimate the maximum tolerated dose of docetaxel in combination with S-1 administered at a fixed dose of 40 mg/m 2 twice daily on days 1-14 of each 3-week cycle in patients with advanced gastric cancer, 60 mg/m2 docetaxel was declared to be the maximum tolerated dose. A phase I/II study of the same schedule of combination chemotherapy with S-1 plus docetaxel reported doses of S-1/docetaxel of 40/75 mg/m2 as the maximum tolerated dose. In a phase I study of S-1 plus weekly docetaxel, the patients received variable doses of docetaxel administered intravenously over 1 h on days 1 and 8 and S-1 administered on days 1-14 of each 3-week cycle. The maximum-tolerated doses of S-1 and docetaxel were determined to be 45 mg/m2 and 35 mg/m2 in this study. A phase I/II study of docetaxel plus S-1 combination chemotherapy from Korea reported a response rate of 43.3%. Also, a phase II study of paclitaxel plus S-1 as first-line therapy in patients with advanced or relapsed gastric cancer showed an overall response rate of 49%. The most frequent significant toxicities in combination chemotherapies with taxane plus S-1 were neutropenia and febrile neutropenia. However, nonhematological toxicities were mild to moderate. A taxane plus S-1 combination regimen could be a new standard regimen for advanced gastric cancer, given its significant activity and favorable toxicity pattern.

AB - Various combination treatments incorporating S-1 are undergoing clinical trials in Korea, especially combinations with taxane, oxaliplatin, or irinotecan. In a phase I study to estimate the maximum tolerated dose of docetaxel in combination with S-1 administered at a fixed dose of 40 mg/m 2 twice daily on days 1-14 of each 3-week cycle in patients with advanced gastric cancer, 60 mg/m2 docetaxel was declared to be the maximum tolerated dose. A phase I/II study of the same schedule of combination chemotherapy with S-1 plus docetaxel reported doses of S-1/docetaxel of 40/75 mg/m2 as the maximum tolerated dose. In a phase I study of S-1 plus weekly docetaxel, the patients received variable doses of docetaxel administered intravenously over 1 h on days 1 and 8 and S-1 administered on days 1-14 of each 3-week cycle. The maximum-tolerated doses of S-1 and docetaxel were determined to be 45 mg/m2 and 35 mg/m2 in this study. A phase I/II study of docetaxel plus S-1 combination chemotherapy from Korea reported a response rate of 43.3%. Also, a phase II study of paclitaxel plus S-1 as first-line therapy in patients with advanced or relapsed gastric cancer showed an overall response rate of 49%. The most frequent significant toxicities in combination chemotherapies with taxane plus S-1 were neutropenia and febrile neutropenia. However, nonhematological toxicities were mild to moderate. A taxane plus S-1 combination regimen could be a new standard regimen for advanced gastric cancer, given its significant activity and favorable toxicity pattern.

KW - Combination chemotherapy

KW - Docetaxel

KW - Gastric neoplasm

KW - Paclitaxel

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=64949134149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949134149&partnerID=8YFLogxK

U2 - 10.1007/s10120-008-0464-9

DO - 10.1007/s10120-008-0464-9

M3 - Article

AN - SCOPUS:64949134149

VL - 12

SP - 31

EP - 37

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - SUPPL. 1

ER -